In 2018, new molecular features have been described including epidermal growth factor receptor (EGFR) amplification, losses of chromosome 10, gains of chromosome 7, and telomerase reverse transcriptase (TERT) promoter mutations to better classify low-grade diffuse astrocytic glioma (WHO grade II or III neoplasm) with evolution close to GBM (Brat et al., 2018; Wesseling and Capper, 2018). Here, EGFR is linked to neoplasm.